ReviewBiochemistry and biophysics reports2025
Emerging hallmarks and the rise of complexities and heterogeneity of tumor.
Review in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated Cytokine, Metabolic, and Proliferative Profiling Reveals Divergent Metabolic and Proliferative Responses in Papillary Thyroid Cancer Cells.International journal of molecular sciences · 2026Article
- Synthesis and Anticancer Activity of New Quinazolin-4(3Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is known for its complexities and heterogeneity due to genetic, epigenetic, known, and unknown environmental components. From time to time, incremental viewpoints on the expanding landscape of tumor hallmarks, including sustained proliferation, evasion of cell death, immune evasion, metabolic reprogramming, and the metabolic-epigenomic-immune axis, are presented. Unifying old and new tumor hallmarks may offer progressive platforms for new diagnostic, therapeutic, and monitoring approaches to therapy responses. Here, we strive to present an updated framework at intracellular, cellular, intercellular, and extracellular levels, assisted by emerging technologies such as OMICS and super-resolution imaging technologies. This review emphasizes that understanding emerging tumor hallmarks may help reveal the dynamics and heterogeneity of tumors. This could lead to sustainable diagnosis, prognosis, and therapeutic management, including precision and personalized approaches for cancer patients. This review presents a unified hierarchical model that connects classical and emerging tumor hallmarks through AI-powered multi-omics integration, emphasizing its conceptual innovation and translational potential in advancing precision oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.